Distribution of HPV Genotype in Invasive Cervical Carcinoma and Cervical Intraepithelial Neoplasia in Zhejiang Province, Southeast China: Establishing the Baseline for Surveillance

Xiao-Xian Xu, Jian-Song Zhou, Shu-Hui Yuan, Hua Yu and Han-Mei Lou
Additional contact information
Xiao-Xian Xu: The Key Laboratory of Radiation Oncology of Zhejiang Province, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China
Jian-Song Zhou: The Key Laboratory of Radiation Oncology of Zhejiang Province, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China
Shu-Hui Yuan: The Key Laboratory of Radiation Oncology of Zhejiang Province, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China
Hua Yu: The Key Laboratory of Radiation Oncology of Zhejiang Province, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China
Han-Mei Lou: The Key Laboratory of Radiation Oncology of Zhejiang Province, Banshan Bridge, Guangji Rd #38, Hangzhou 310022, China

IJERPH, 2015, vol. 12, issue 9, 1-12

Abstract: Human papillomavirus (HPV) are firmly established as the principal causative agent for cervical carcinoma. Current vaccines may provide some protection for women from cervical carcinoma linked to HPV genotype 16 and 18. This may be the best vaccine for Western women, but the geographical variation in HPV distributions may not make it the most appropriate vaccine for China or Asia. This study provided an observational, retrospective, hospital-based cross-sectional study on the distribution of HPV genotypes among 5410 women with invasive cervical cancer (ICC) or cervical intraepithelial neoplasia (CIN). Overall, the positive rates of the four HPV types included in current prophylactic vaccines were counted, the two high-risk types (HPV-16 and -18) covered by current vaccines represented 66.9% of women with squamous cancer, 55.0% with adenocarcinoma, 64.9% with adenosquamous carcinoma and 77.4% of other type ICC, as well as 59.5% of CIN III, 45.0% of CIN II and 38.1% of CIN I cases. As expected, two low-risk types (HPV-6 and -11) included in the quadrivalent vaccine did not show good coverage data. Particularly worth mentioning is the fact that the addition of HPV-52 and -58 to the vaccine cocktail would increase cancer protection in our population, potentially preventing up to beyond 16% of squamous/adenosquamous carcinoma and other type of cervical cancers, and 7.75% of adenocarcinomas. It might also potentially reduce the rate of CIN III by a further 28.6% and CIN II and I by a third. This study established the baseline for surveillance in Zhejiang Province, and provides data for further vaccine designs: a quadrivalent HPV vaccine covering HPV-16/-58/-18/-52, would be more welcome in our region in the forthcoming year compared to the currently available vaccine.

Keywords: HPV; vaccine; cervical; ICC; CIN; genotype (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2015
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/12/9/10794/pdf (application/pdf)
https://www.mdpi.com/1660-4601/12/9/10794/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:12:y:2015:i:9:p:10794-10805:d:55161

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().